The start-up team was confident. Their Class II device had promising bench data, strong engineering, and investors eager for a quick FDA clearance. Yet two months after filing their 510(k), the company received an Additional Information (AI) request that stopped the review clock. The issue wasn’t safety or technology—it was an unclear predicate strategy. That single misstep delayed the launch by almost a year and drained precious capital.
This is the hidden reality of the 510(k) program. While often seen as the “easier” route compared to premarket approval (PMA), the process is deceptively complex. And for sponsors, the stakes are massive: mismanaging a 510(k) can result in lost time, credibility, and millions in revenue.
Why 510(k) Still Dominates
According to FDA data, over 3,000 510(k) submissions are filed each year, making it the most common pathway to market. Unlike PMAs, which require demonstrating safety and effectiveness from scratch, the 510(k) relies on proving “substantial equivalence” to a legally marketed predicate. That means the new device must share the same intended use and either the same technology, or differences that don’t raise new safety and effectiveness concerns.
Yet this comparative standard is a double-edged sword. It can accelerate clearance in 90 days—or sink a device if sponsors underestimate how rigorouslythe FDA applies the equivalence test.
The Sponsor’s Dilemma: Predicate or Pitfall?
Predicate selection has become one of the most critical—and misunderstood—steps in the process. Sponsors often assume any similar device can serve as a predicate. But FDA reviewers apply a structured flowchart (outlined in the 510(k) Program Guidance) that demands legal marketing status, consistent intended use, and technological comparability.
When sponsors attempt a “split predicate”—using one device for intended use and another for technology—FDA rejects it outright.
“Substantial equivalence is the whole point of the 510(k) program,” said Lt. Commander Kimberly Piermatteo, a Regulatory Operations Officer at FDA/CDRH, during her training course. “Either your predicate device was not legally marketed, or not appropriate. And it could be that your predicate device has new intended use compared to predicate device”
For sponsors, it’s a matter of strategy. Choosing the wrong predicate can derail commercialization plans, leaving investors skeptical and competitors advancing unchallenged.
Lessons From Infusion Pumps
Consider infusion pumps, one of the most frequent 510(k) device categories. FDA’s Product Classification Database not only identifies the correct three-letter product code (FRN) but also lists recognized consensus standards and device-specific guidance. Sponsors who leveraged those standards in past submissions often moved through clearance efficiently, while those who ignored them faced AI holds and rework.
This case illustrates a broader lesson: FDA doesn’t expect novelty in 510(k)s—it expects consistency. Sponsors who “color inside the lines” of guidance documents, labeling templates, and predicate comparisons are rewarded with speed. Those who improvise risk costly detours.
The Timelines Sponsors Forget
Sponsors often underestimate how structured the FDA’s 510(k) review timeline is:
- Day 1: Submission received.
- Day 7: Acknowledgment or hold (usually user fee or eCopy issues).
- Day 15: Acceptance review → possible RTA (Refuse to Accept) hold.
- Day 60: Substantive interaction—either interactive review or formal AI request.
- Day 90: MDUFA decision for traditional/abbreviated 510(k)s.
When sponsors miss the nuances—such as responding late to AI requests (which stop the FDA clock for up to 180 days)—the “90-day clearance” can easily stretch to 9–12 months. For small companies, that delay can mean the difference between a successful Series B and shutting down.
Clinical Data: The Rare but Real Requirement
Most 510(k)s don’t require clinical studies. But exceptions are increasing. New indications, significant tech modifications, or situations where bench testing is inadequate may trigger the FDA’s request for clinical data.
This is where sponsors often stumble—caught off guard, with no protocol in place, and scrambling to collect data under pressure from investors. Proactive sponsors are now engaging the FDA through the Pre-submission Program to de-risk this uncertainty.
The Emerging Sponsor Playbook
From our analysis of FDA guidance, case studies, and sponsor experiences, a playbook for success is emerging:
- Start With the Database. Use the FDA’s product classification database early to determine codes, standards, and guidance.
- Treat Predicate Like Strategy. Vet multiple candidates, verify marketing status, and avoid “split” reasoning.
- Stay Consistent. Align intended use language across IFU, labeling, and summaries—reviewers can instantly catch inconsistencies.
- Plan for AI. Assume you’ll receive an Additional Information request. Have resources and timelines ready to respond within weeks, not months.
- Consider Pre-Subs. Particularly if clinical data may be requested or the predicate fit is uncertain.
Final Thought: The 510(k) Is a Business Decision
Too many sponsors still view the 510(k) as paperwork. In reality, it’s a business-critical milestone that dictates market timing, investor confidence, and competitive positioning.
FDA clearance isn’t just a regulatory checkbox—it’s a market signal. And in the race to bring devices to patients, those who master the subtleties of the 510(k) process will outpace those who treat it as an afterthought.
The difference isn’t academic. It’s survival.
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
